新天地药业股份有限公司2025年度报告详细解读

一、报告摘要与关键信息

新天地药业股份有限公司（证券代码：301277，简称“新天地”）发布了2025年度报告摘要。2025年公司实现营业收入6.72亿元，同比下降7.44%；归属于上市公司股东的净利润为1.21亿元，同比大幅下降30.17%。扣除非经常性损益后的净利润为1.08亿元，同比下降32.40%。
公司董事会已审议通过利润分配预案，拟以3.92亿股为基数，向全体股东每10股派发现金红利2元（含税），未送红股，未以资本公积转增股本。

二、主营业务及产品情况

• 医药中间体业务：
  • 公司为全球主要左旋对羟基苯甘氨酸生产企业，该产品为合成阿莫西林、头孢羟氨苄、头孢哌酮等抗生素原料药的关键中间体。
  • 公司在对甲苯磺酸领域也具备领先地位，产品覆盖工业级、医药级及高纯级，应用于涂料、树脂固化剂、电镀、抗生素、抗肿瘤等多个领域，并积极拓展高端电子化学品市场。
• 原料药业务：
  • 公司拥有13个原料药产品在中国注册获批，覆盖抗感染、糖尿病、局部麻醉等多领域，主要包括盐酸利多卡因、盐酸萘甲唑啉、维格列汀、盐酸莫西沙星、艾司奥美拉唑镁、他达拉非等。
  • 在研原料药有6个品种已提交注册。产品管线不断丰富，已与白云山、仁和药业、国药集团、鲁抗医药等90余家客户建立合作，部分产品成为主流供应商。
  • 国际注册方面，磺达肝癸钠、盐酸莫西沙星已完成美国DMF备案，部分产品正推进欧洲CEP注册。
• 制剂业务：
  • 公司依托中间体与原料药领域优势，推动一体化协同发展。维格列汀片已获药品注册证书，盐酸莫西沙星片、注射液、磷酸奥司他韦胶囊等项目有序推进。
  • 一体化布局有助于成本控制、质量管控，为后续规模化生产和市场拓展奠定基础。

三、财务数据与关键指标

本年度业绩下滑，主要体现在营收和利润端的双降，扣非净利润降幅更为明显，显示主营业务盈利能力承压。

四、分红方案及股本结构

• 2025年拟每10股派发现金红利2元（含税），合计派现约7,841万元。
• 截至2025年末，普通股股东总数为17,741户，前两大股东为河南双洎实业有限公司（持股63.21%）和长葛市中远商贸有限公司（持股11.02%），实际控制人为谢建中。
• 主要股东之间存在一定关联关系，需关注潜在的公司治理及决策一致性风险。

五、潜在影响与投资者关注的敏感信息

• 业绩大幅下滑：2025年收入和净利润均出现明显下降，或对股价形成压力，投资者需关注业绩恢复情况及后续增长潜力。
• 持续分红：公司继续分红，展现回馈股东意愿，但分红水平有所下降，需关注未来分红政策稳定性。
• 国际化进展：部分原料药已完成美国和欧洲注册，有助于开拓海外市场，构成中长期利好。
• 新产品研发及管线丰富：持续投入研发，推动制剂业务和高端应用领域拓展，若新产品快速放量，业绩有望改善。
• 公司治理结构：实际控制人及关联方持股集中，需关注潜在的公司治理风险。

六、结论

综合来看，新天地药业2025年业绩下滑显著，短期内或对公司估值和股价形成压力。但公司在医药中间体、原料药和制剂领域具备一定行业地位，持续推进国际化和新产品研发，若能成功实现市场拓展及产品放量，业绩有望回暖。投资者需结合公司中长期发展规划、分红政策及治理结构进行全面评估。

免责声明：本文仅为基于公开年报信息的新闻解读，不构成任何投资建议。投资有风险，决策请谨慎。

English Translation

Detailed Analysis of New Land Pharma 2025 Annual Report

1. Report Highlights and Key Points

New Land Pharma Co., Ltd. (stock code: 301277, “New Land”) released its 2025 annual report summary. In 2025, the company achieved revenue of RMB 672 million, down 7.44% year-on-year; net profit attributable to shareholders was RMB 121 million, a sharp decline of 30.17%. Net profit after deducting non-recurring gains/losses was RMB 108 million, down 32.40% year-on-year.
The board approved a profit distribution plan: based on 392 million shares, a cash dividend of RMB 2 (tax included) per 10 shares will be distributed to all shareholders, with no bonus shares or capital reserve conversion.

2. Main Business and Product Overview

• Pharmaceutical Intermediates:
  • The company is a major global producer of L-p-Hydroxyphenylglycine, a key intermediate for Amoxicillin, Cefalexin, Cefoperazone and other antibiotics.
  • It also leads in p-Toluenesulfonic acid, with products covering industrial, pharmaceutical, and high-purity grades, widely used in coatings, resin curing agents, electroplating, antibiotics, anti-tumor, and high-end electronic chemicals. The company actively expands into high-end applications.
• Active Pharmaceutical Ingredients (APIs):
  • 13 APIs have domestic registration approval, covering anti-infection, diabetes, local anesthesia, etc., including Lidocaine Hydrochloride, Naphazoline Hydrochloride, Vildagliptin, Moxifloxacin Hydrochloride, Esomeprazole Magnesium, Tadalafil, etc.
  • Six APIs under registration; the company collaborates with over 90 clients including Baiyunshan, Renhe Pharma, Sinopharm, Lukang Pharma, with some products as mainstream suppliers.
  • Internationally, Fondaparinux Sodium and Moxifloxacin Hydrochloride have completed US DMF filings, and some products are undergoing CEP filings in Europe.
• Formulations:
  • Leveraging its intermediate and API advantages, the company pushes for integrated development. Vildagliptin tablets obtained drug registration; Moxifloxacin tablets and injection, Oseltamivir phosphate capsules, and Ruxolitinib phosphate tablets are underway.
  • Integration supports cost and quality control, laying a solid foundation for future scale production and market expansion.

3. Financial Data and Key Indicators

The company saw both revenue and profit decline, with a steeper drop in core operating profit, indicating pressure on main business profitability.

4. Dividend Plan and Share Structure

• 2025 dividend: RMB 2 cash (tax included) per 10 shares, totaling about RMB 78.41 million.
• At year-end, there were 17,741 ordinary shareholders. The top two shareholders are Henan Shuangji Industrial (63.21%) and Changge Zhongyuan Trading (11.02%). The actual controller is Xie Jianzhong.
• There are certain relationships among main shareholders; investors should monitor possible governance and decision-making risks.

5. Potential Impacts & Price-Sensitive Information

• Significant Earnings Decline: Both revenue and profit dropped sharply in 2025, potentially pressuring the share price. Investors should watch for recovery signs and growth potential.
• Continued Dividend: The company keeps paying dividends, showing shareholder return commitment, though the payout level has decreased.
• International Progress: Some APIs have passed US/Europe filings, supporting future overseas market expansion—a medium/long-term positive.
• New Product Pipeline: R&D continues, with focus on high-end and formulation business. Success in new product commercialization could improve performance.
• Governance Structure: Shareholding is concentrated among actual controllers and affiliates; potential governance risks should be monitored.

6. Conclusion

Overall, New Land Pharma’s 2025 performance has declined significantly, likely pressuring valuation and share price in the short term. However, the company maintains a solid position in intermediates, APIs, and formulations, and continues to pursue internationalization and pipeline expansion. If successful, performance could rebound. Investors are advised to assess the company based on its long-term strategy, dividend policy, and governance.

Disclaimer: This article is for informational purposes based on public annual report data. It does not constitute investment advice. Investing is risky; please make decisions prudently.

View 新天地 Historical chart here